Will Intellia finalize NTLA-2002 dosing for pivotal trials by September 30, 2024?

When will the NTLA-2002 pivotal trial start?

Which dosing will Intellia select for NTLA-2002 pivotal trials by September 30, 2024?

Will Intellia announce a partnership for NTLA-2002 commercialization by December 31, 2024?

Outcome of First Regulatory Review for Regeneron-Mammoth CRISPR Therapy by 2026

First Disease Targeted for CRISPR Therapy by Regeneron-Mammoth

Expansion of Regeneron-Mammoth Partnership Beyond CRISPR by 2025

Regeneron Increases Equity in Mammoth by 2026

Number of New Diseases Targeted by Regeneron-Mammoth by 2025

First Disease Targeted by Regeneron-Mammoth CRISPR Collaboration

First Human Trials of Regeneron-Mammoth CRISPR Therapy by 2025

Regeneron Outperformance of S&P 500 by End of 2024

FDA Approval of Regeneron-Mammoth CRISPR Therapies by 2027

Greater Revenue Growth in 2024: Regeneron vs Mammoth Biosciences

Regeneron Milestone Payment to Mammoth by End of 2024

Will Harvard's gene therapy for Diamond-Blackfan Anemia receive FDA approval by end of 2025?

At which major medical conference will Intellia present NTLA-2002 data by December 31, 2024?

Successful Phase 1 CRISPR Trial by End of 2025

Will Intellia's CRISPR therapy be FDA approved for ATTR-CM by end of 2025?

Will NTLA-2002 receive Fast Track designation from FDA by December 31, 2024?

What level of cardiomyopathy improvement will Intellia's CRISPR therapy show by end of 2025?

What market share will Intellia's CRISPR therapy hold over Alnylam's by end of 2026?

What level of transthyretin reduction will Intellia's CRISPR therapy achieve by end of 2025?

Will Intellia's CRISPR therapy outperform Alnylam's siRNA therapy by end of 2025?

Will Intellia's CRISPR therapy enter Phase 2 trials for ATTR-CM by mid-2025?

Will Intellia's CRISPR treatment for ATTR enter Phase 2 trials by end of November 2025?

What will be the primary outcome of Intellia's CRISPR treatment Phase 1 study for ATTR by end of 2024?

What will be the dominant therapeutic approach for Diamond-Blackfan Anemia by 2026?

What will be the outcome of Gilead's Livdelzi Phase 3 study for PBC by end of 2024?

Will Gilead's Livdelzi launch commercially in the US by mid-2025?

Which milestone will Intellia's CRISPR treatment for ATTR-CM reach by end of 2025?

FDA approval for Intellia's CRISPR treatment for ATTR-CM by end of 2024?

Number of new adverse events in Intellia's CRISPR Phase 2 trials by end of 2025?

Percentage of patients with improved 6MWT results from Intellia's CRISPR treatment by end of 2025?

Superior 6MWT results for Intellia's CRISPR treatment in Phase 2 by end of 2025?

50% reduction in adverse events for Intellia's CRISPR treatment by end of 2025?

When will Intellia complete enrollment for Phase 3 study of NTLA-2002 by 2025?

Will NTLA-2002 receive FDA Breakthrough Therapy Designation by end of 2025?

Will Intellia start Phase 3 trial of NTLA-2002 for HAE by end of 2025?

Will NTLA-2002 demonstrate over 90% attack reduction in Phase 3 by end of 2026?

Which in vivo CRISPR therapy will be first to receive FDA approval by 2026?

When will Intellia complete Phase 3 study of NTLA-2002 by 2026?

Will NTLA-2002 receive FDA approval for HAE by end of 2025?

Will Intellia complete HAELO Phase 3 trial enrollment by mid-2025?

Will NTLA-2002 show superior efficacy to lanadelumab in Phase 3 trial by end of 2025?

What will be the outcome of NTLA-2002 Phase 3 trial for HAE by end of 2025?

What will be NTLA-2002's market share in HAE treatment by end of 2026?

How will Intellia's stock price change within 30 days of Phase 3 results announcement?